Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016

Similar documents
Pfizer Support to European and International Patient Organisations in 2008

THE VALUE OF TREATMENT FOR BRAIN DISORDERS A NEW VISION IN PROGRESS...

Counting down to zero

Country Disease Area Patient Advocacy Group Name Description of the Contracted Services (when applicable)

International Bureau for Epilepsy MEMBERSHIP GUIDE Benefits and Responsibilities

The European Brain Council

Not Myself Today Europe Project Development

The basics a. Mission Statement (unchanged) eurordi s.org

Support to Patient Organisations 2016

Prevention and control of viral hepatitis: the role and impact of patient and advocacy groups in and outside Europe. Lucca, Italy March 2008

Joint Programming in Neurodegenerative Disease Research (JPND)

RD-ACTION DISSEMINATION PLAN TABLE I - STAKEHOLDER ANALYSIS

World Hepatitis Alliance Strategic Plan 2015

Pfizer Healthcare Ireland Patient Association Funding Disclosure 2017

Pfizer Healthcare Ireland Patient Association Funding Disclosure 2013

1. The Working Party on Public Health discussed and agreed the draft Council conclusions as set out in the Annex.

The Life Course Immunisation Initiative

During 2012, Pfizer supported Age Concern with the following:

POSITION DESCRIPTION. Employment Status: Maternity Leave Contract 5 months (Jan-May 2018) PURPOSE OF POSITION DESCRIPTION

A pan European Dementia Strategy

Joint Programming Initiative on Neurodegenerative Diseases. Prof. Philippe Amouyel Chair, JPND Management Board

VALUE TO A SPONSOR PARTNER OR DONOR. Dementia Alliance International

Table Of Content. Page 1/8

Annual Report 2012/2013

4. Project Inform does receive restricted donations from corporations, non-profits, foundations, and government entities.

Council of the European Union Brussels, 28 October 2015 (OR. en)

Adding Value to the NHS, Health and Care, through Research Management, Support & Leadership

PHOTO. VHPB/ELPA MEETING Prevention and Control of Viral Hepatitis The role and impact of patients and advocacy groups in and outside Europe

Barbra Bohannan Head of Operations and Strategic Communications

Cancer Research in the EU Framework Programmes for RTD

ALCOHOL, TOBACCO & OTHER DRUGS COUNCIL TAS INC.

BUILDING A SUPPORTIVE FRAMEWORK FOR BRAIN RESEARCH IN IRELAND INAUGURAL POSITION PAPER THE IRISH BRAIN COUNCIL

Health and Social Care Alliance Scotland: People at the Centre

MRCG Strategic Document

Table Of Content. EURORDIS_FY Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7

European Brain Council: Structure and activities. Jes Olesen President European Brain Council (EBC)

Irish Experts Launch Global Report and Call for Increased Focus on Metastatic Breast Cancer

Making dementia a European priority

STRATEGIC APPROACH & WORKPLAN 2007

BDA IMPROVING ONCOLOGY DRUG DEVELOPMENT FOR CHILDREN AND ADOLESCENTS NOVEMBER 2013 WORKSHOP ADVANCE PROGRAMME

MEN S HEALTH AND PRIMARY CARE: IMPROVING ACCESS AND OUTCOMES

Carers Australia Strategic Plan

ESMO 2020 VISION. esmo.org

The challenge of vaccine hesitancy in the European Union

International Kidney Cancer Coalition. Patient Organisations Working Together Globally to Support Those Affected by Kidney Cancer

European Parliament Interest Group on Mental Health, Well-being and Brain Disorders

CHARTING THE COURSE FOR CANADA S NATIONAL DEMENTIA STRATEGY PRE-BUDGET SUBMISSION TO THE HOUSE OF COMMONS STANDING COMMITTEE ON FINANCE

The G8 Dementia Summit: A Giant Step Forward for Dementia

Position Description Ovarian Cancer Australia Support Coordinator, Support Programs

EuropaColon Expands into Digestive Cancers Europe. Our objective is to save an additional 250,000 Europeans every year

A progress report on the Joint Programming Initiative

DEMENTIA: IMPLEMENTATION REPORT AND CURRENT DEVELOPMENTS EU HEALTH

Consultation on Australian Medical Research and Innovation Priorities for

What EU research policy can do for conditions such as chronic pain?

Rare Cancer Perspective in the EUCERD

A multi-stakeholder partnership initiative. 10 February 2012

Terms of Reference for the Clinical Board of the Pumping Marvellous Foundation

ENDING HOMELESSNESS WHY WE NEED MORE SOCIAL INNOVATION AND INVESTMENT

Mental Health Matters

DECEMBER 2012 PAYMENTS

DSQC Overview. Scott Kuzner, Ph.D. USP Global External Affairs Director

DRAFT STRATEGIC APPROACH & ACTION PLAN For consultation at RDI Annual Meeting Edinburgh, Scotland May 25, 2016

EPDA EUROPEAN PARKINSON S DISEASE ASSOCIATION

Transparency in drug regulatory decision making Why transparency? Birthe Byskov Holm, Rare Diseases Denmark Copenhagen October

INTERNATIONAL STILLBIRTH ALLIANCE STRATEGIC DIRECTIONS AND GOALS FOR

ECPC ANNUAL CONGRESS ECPC GENERAL ASSEMBLY

EUPATI beyond January 2017 Nicola Bedlington and the EUPATI Team

NORDIC CONFERENCE ON RARE DISEASES

SUPPORTING EMPLOYEES WITH CANCER: THE CANCER CARE HUDDLE. March 26, 2018

The summit and its purpose

Contribute to our vision of saving lives and ensuring no woman with ovarian cancer walks alone

Future of Diabetes Research in Europe JDRF Perspective

Affecting Change... Public affairs, campaigning & political. Caroline Collins, PhD Public Affairs Manager The Alzheimer Society of Ireland March 2012

SCOTTISH PARLIAMENTARY EVENT 12 TH NOVEMBER 2014

COMMISSION OF THE EUROPEAN COMMUNITIES

Addressing Gaps in MS Care. November 6, :00 AM - Noon

Harmonized Salt Iodization future policy approach to achieve the mission and vision in eliminating Iodine deficiency in Europe

Welcome Note by Dr. Helge Braun, Parliamentary State Secretary

CYPRUS PRESIDENCY OF THE COUNCIL OF THE EU

Political advocacy: a way to achieve better outcomes for people with Parkinson s disease and their families A workshop on engaging effectively with

European Patients Academy on Therapeutic Innovation

Covenant on Demographic Change. Anne-Sophie PARENT, 10/11/2015

Non communicable diseases

Novo Nordisk Pharma AG Methodology Note - reporting year 2016 ( Methodology )

The Global Network Aiming to deliver safe quality care in relation to tobacco for every service user, every time and everywhere

Consultation on Strengthened EU cooperation against vaccine preventable diseases

EU Funding for Global Health Research and Development (GH R&D) Cecile Vernant, Head of EU Advocacy, DSW EU 13 June 2014

Position paper on a patient-centred, affordable and sustainable system for incontinence* aids

Advocates Rights Actors Justice for

We are here for our fellow patients

Terms of Reference: PR and Media Officer ENDAIDS2030 Festival

The European Asthma Research & Innovation Partnership tackling Europe s high asthma prevalence and death rates

GAMIAN-Europe Annual Activity Report 2017

MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA

Agenda 2030: One Nation Labour s Plan for science Response from Alzheimer s Research UK

The Data Collection on Adverse events of Anti-HIV Drugs

Multisectoral action for a life course approach to healthy ageing

On 24 May 2005 the Council (GAERC), in its formation of Development Ministers, adopted the conclusions in Annex I.

General Assembly. United Nations A/63/152/Add.1

Transcription:

Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016 Please note that all information in this document is also disclosed in the overall report on Pfizer Support to European and International Patient Organisations based in Europe in 2016 here. Support to European organisations The below list contains information on the support Pfizer has provided to European-level patient organisations based in Belgium & Luxembourg in 2016, and services contracted from them (e.g. speaker fees), and to national and global patient organisations for European-level work. Alzheimer Europe Alzheimer Europe is a non-governmental organisation aimed at raising awareness of all forms of dementia by creating a common European platform through co-ordination and co-operation between Alzheimer organizations throughout Europe. Alzheimer Europe is also a source of information on all aspects of dementia. Pfizer Inc provided 20,000 to support Alzheimer Europe s public affairs activities. European Cancer Patient Coalition Established in 2003, the European Cancer Patient Coalition is the voice of the European cancer patient community, uniquely representing the interests of all cancer patient groups from the most common to the rarest forms of cancer. 15,000 Pfizer Inc provided support for the Value of Innovation project in 2016. 15,000 Pfizer Inc provided support for ECPC s 2016 Annual General Meeting in Brussels. 62,000 Pfizer Inc provided advanced support for the ECPC s Immuno-Oncology Portal in 2017. European Federation of Chrohn s and Ulcerative Colitis Associations (EFCCA) EFCCA is a European umbrella organisation representing 33 national patients associations. EFCCA aims to work to improve life for people with IBD and give them a louder voice and higher visibility across Europe and beyond. 8,500 Pfizer S.r.l. provided an educational grant for the EFCCA Network Communications platform. 10,000 Pfizer S.r.l. provided an educational grant for the EFCCA Patient Safety education 1

programme. 10,000 Pfizer S.r.l. provided an educational grant for translation of the European ECCO Guidelines project. 10,000 Pfizer S.r.l. provided an educational grant for the EU stakeholder mapping project. European Federation of Neurological Associations (EFNA) The European Federation of Neurological Associations (EFNA) brings together European umbrella organisations of neurological patient advocacy groups, to work with other associations in the field of neurology, in what has been termed a Partnership for Progress. EFNA engages in activities, which contribute to the advancement of neurology and related areas with a view to improving the quality of life of people living with neurological conditions, their families and carers. Pfizer Inc provided 50,000 to support EFNA s Under the Umbrella communications campaign and MEP interest group meetings. European Haemophilia Consortium (EHC) The European Haemophilia Consortium (EHC) is a European patient group representing national member organisations from 43 countries in Europe including members in all 28 Member States. The EHC is working to reduce the burden of the disease on both the individual and on society. Its mission is to improve the quality of life of people with Haemophilia in Europe. Pfizer Inc provided 60,000 as sponsorship of the EHC workshop on economics and health technology assessment. European Men's Health Forum (EMHF) The European Men s Health Forum (EMHF) is the only European organisation dedicated to the improvement of men s health in all its aspects, and a platform for the collaboration of a wide range of stakeholder groups in Europe. It aims to promote collaboration between interested individuals and organisations on the development and application of health policies, research, education and prevention programmes. In addition, EMHF strives to raise the profile of men s health issues across Europe, develop Europe-wide policies and support the establishment and development of men s health organisations that pursue similar objectives in each European country. Pfizer Inc provided 37,000 to support the EMHF project to improve men's use of pharmacy services across Europe. European Patients' Forum (EPF) 2

The European Patients Forum (EPF) is the umbrella patients organisation at EU level. It brings together a broad range of leading European and national patients organisations in different disease areas. Representing over 150 million patients, the EPF is a key interlocutor with European institutions, and promotes patients rights, participation and involvement in EU healthcare developments. 40,000 Pfizer SA provided a grant to support EPF s annual work programme. 25,000 Pfizer Inc provided a grant support to EFF s Capacity Building Programme (payment initiated by Pfizer in 2016, received by EPF in 2017). 6,250 Pfizer Inc provided a healthcare charitable contribution for journal access for EUPATI fellows. GAMIAN Europe GAMIAN Europe (Global Alliance of Mental Illness Advocacy Networks Europe) is a pan-european patient-driven federation of organisations across Europe assisting people affected by mental illness. Its main objectives are: advocacy, information and education, anti-stigma and discrimination, patients rights, cooperation, partnerships and capacity building. Pfizer Inc provided a 20,000 grant to support GAMIAN Europe s mental health and sexual health study. International Diabetes Federation Europe (IDF-Europe) As the only European advocate for people with diabetes and their healthcare providers, the International Diabetes Federation European Region works together with its member associations and other diabetes stakeholders to enhance the lives of people with diabetes. Many IDF member associations are made up of people with diabetes and health care professionals. The mission of the International Diabetes Federation is to promote diabetes care, prevention and a cure worldwide. Pfizer Ltd provided 27,000 as a membership fee to IDF-Europe. Stroke Alliance for Europe (SAFE) SAFE is a non-profit-making organisation that represents a range of patient groups from across Europe whose mutual goal is to drive stroke prevention up the European political agenda and prevent the incidence of stroke through education. 24,327 Pfizer Ltd on behalf of the BMS-Pfizer Alliance (an alliance between Bristol- Myers Squibb Pharmaceuticals Ltd and Pfizer Ltd) provided sponsorship for The 3

Burden of Stroke Report. This figure is the total of Pfizer s contribution via the Pfizer-BMS Alliance, and is 50% of the total paid. 1,040 Pfizer Ltd on behalf of the BMS-Pfizer Alliance (an alliance between Bristol- Myers Squibb Pharmaceuticals Ltd and Pfizer Ltd) provided an independent speaker honorarium to ACE. This figure is the total of Pfizer s contribution via the Pfizer-BMS alliance, and is 50% of the total paid. European Huntington Association Pfizer Inc provided 7,500 to support the E H A annual meeting. 4

Appendix: to organisations engaged in some work with patients. Pfizer provides funding to a number of organisations that are not patient organisations, but which have patient organisation membership or are otherwise relevant to patients. As such, they are listed here for the sake of transparency. European Alliance for Personalised Medicine (EAPM): Founded in 2012, The European Alliance for Personalised Medicine (EAPM) brings together Europe s leading healthcare experts, healthcare organisations and institutions, and patient advocates to improve patient care by accelerating the development, delivery and uptake of personalised healthcare including personalised medicine and diagnostics. EAPM is based in Belgium. In 2016, Pfizer Inc. paid 50,000 to cover annual membership fees for 2015 and 2016, and 25,000 to cover annual membership fees for 2017. European Brain Council (EBC): The European Brain Council (EBC) is a coordinating council formed by European organisations in neurology, neurosurgery, psychiatry, basic brain research (neuroscience), as well as patient organisations and companies from within the pharma and biotech industries. It represents a vast network of patients, doctors and scientists, and these stakeholders along with its industrial partners make it eminently suited to work in close partnership with the European Parliament and Commission, national governments as well as other policy making bodies. EBC is based in Belgium. In 2016 Pfizer Ltd provided EBC with 20,000 as an annual membership fee. An additional funding of 109.000 USD has been paid in 2016 for project agreed in November 2015 with Pfizer Inc. and Pfizer Ltd. on the value of non-treatment to develop a position paper: Integrating brain disorders in the holistic management of chronic conditions in Europe : development of a workable care model and case studies analysis. 5